Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MASS syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    574 result(s) found for: MASS syndrome. Displaying page 5 of 29.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000387-14 Sponsor Protocol Number: RM-493-014 Start Date*: 2017-05-24
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity
    Medical condition: - POMC/PCSK1/LEPR heterozygous - POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesity - POMC/PCSK1/LEPR composite heterozygous deficiency obesity - Smith-Magenis Syndrome - SH2B1...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) FR (Ongoing) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000161-40 Sponsor Protocol Number: AdrenalClock Start Date*: 2022-07-18
    Sponsor Name:Medical University of Vienna, Division of Endocrinology
    Full Title: Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion
    Medical condition: Autonomous cortisol secretion in patients with adrenal adenoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000775-42 Sponsor Protocol Number: RIMON_L_00075 Start Date*: 2007-12-27
    Sponsor Name:University Hospital Tübingen
    Full Title: Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial
    Medical condition: overweight, obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003250-34 Sponsor Protocol Number: IVI-ERA-2011 Start Date*: 2011-12-13
    Sponsor Name:IVI Madrid
    Full Title: Endometrial receptivity with different support protocols for the luteal phase in ovarian stimulation cycles in which final oocyte maturation is carried out with GnRH analogues. Analysis by endometr...
    Medical condition: Ovarian Hyperstimulation Syndrome (OHSS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10033266 Ovarian hyperstimulation syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001465-41 Sponsor Protocol Number: CBPS804A2201 Start Date*: 2011-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label intra-patient dose escalation study with an untreated reference group to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple infusions of B...
    Medical condition: Patients with previously established diagnosis of osteogenesis imperfecta (OI). OI is a rare genetic disorder of the connective tissue characterized by bone fragility and reduced bone mass. OI comp...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002486-21 Sponsor Protocol Number: GLY-311-2017 Start Date*: 2018-01-18
    Sponsor Name:GLyPharma Therapeutic, Inc. (a wholly owned subsidiary of VectivBio Holding AG)
    Full Title: A once weekly, repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and pharmacodynamics of FE 203799 in patients with short bowel syndrome wi...
    Medical condition: Short Bowel Syndrome (SBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004866-33 Sponsor Protocol Number: CA-BP13 Start Date*: 2014-04-04
    Sponsor Name:Göteborgs Universitet
    Full Title: A short term open, randomized cross over trial trial exploring the effect of carbonic anhydrase inhibition by acetazolamide on sleep apnea associated hypertension
    Medical condition: obstructive sleep apnea related hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015859-24 Sponsor Protocol Number: Zon-001 Start Date*: 2010-02-24
    Sponsor Name:The Sahlgrenska Academy, University of Gothenburg
    Full Title:
    Medical condition: The objective is to explore the efficacy of pharmacological weight reduction compared with CPAP treatment in patients with moderate to severe obstructive sleep apnea (OSA).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004266-15 Sponsor Protocol Number: ARYHM-1 Start Date*: 2012-01-18
    Sponsor Name:RMC, Skåne University Hospital
    Full Title: Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study
    Medical condition: Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile H...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10067734 Testosterone deficiency LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002240-17 Sponsor Protocol Number: ATR-101-301 Start Date*: 2017-05-16
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome
    Medical condition: endogenous Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005006-35 Sponsor Protocol Number: RM-493-022 Start Date*: 2018-05-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 recepto...
    Medical condition: Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genet...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000397-23 Sponsor Protocol Number: SLx-2101-07-04 Start Date*: 2007-05-29
    Sponsor Name:Surface Logix, Inc.
    Full Title: A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days ...
    Medical condition: Raynaud's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037917 Raynauds LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004503-39 Sponsor Protocol Number: IG1104 Start Date*: 2015-01-28
    Sponsor Name:Instituto Grifols, S.A.
    Full Title: A multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group clinical trial to assess the efficacy and safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF...
    Medical condition: Patients with Post-polio syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10036239 Post polio syndrome PT
    17.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) ES (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000352-16 Sponsor Protocol Number: D5130C00002 Start Date*: 2004-09-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segm...
    Medical condition: Non-ST Segment Elevation Acute Coronary Syndromes
    Disease: Version SOC Term Classification Code Term Level
    7.0 10051592 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) ES (Completed) CZ (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003147-30 Sponsor Protocol Number: 1103-CT02 Start Date*: 2012-11-20
    Sponsor Name:Antisense Therapeutics Ltd
    Full Title: A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-005448-32 Sponsor Protocol Number: DIUR-006 Start Date*: 2016-07-20
    Sponsor Name:Diurnal Ltd
    Full Title: A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia (CAH)
    Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020154-33 Sponsor Protocol Number: RTG113388 Start Date*: 2012-03-09
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures(≥12 years old) and Subjects with Lennox-Gastaut Syndrome (≥12 ...
    Medical condition: Uncontrolled partial onset seizures or Lennox Gastaut Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061334 Partial seizures PT
    14.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000397-19 Sponsor Protocol Number: Ctrl-DM2 Start Date*: 2014-09-09
    Sponsor Name:University Medical Center Groningen
    Full Title: Effects of Combined Treatment of Surgery and Liraglutide on Glycemic Variability and Control in type 2 Diabetes Mellitus: The Ctrl-DM2 Study
    Medical condition: type 2 diabetes with morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019892-31 Sponsor Protocol Number: 65759682 Start Date*: 2011-06-15
    Sponsor Name:Lightlake Sinclair Oy
    Full Title: Hoitotutkimus BED-syömishäiriöstä ja sen taustatekijöistä
    Medical condition: Binge Eating-Disorder, BED on ylipainoisilla esiintyvä syömishäiriö, jolle on luonteenomaista ahminta. Tutkimuksessa selvitetään nasaalisen (nenän kautta annosteltavan) naloksonilääkkeen tehoa BES ...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10004716 Binge eating PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000383-27 Sponsor Protocol Number: D1803C00002 Start Date*: 2004-07-28
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowe...
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 12:09:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA